CAH · Cardinal Health Inc
$235.17
+3.93 (+1.70%)
At close · Aug 14
Market Cap
$54.69B
Shares
232.58M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$254.25B
+14.2%
FY2026
Net Income
$1.71B
+9.8%
FY2026
Gross Margin
3.84%
+0.2pp
FY2026
Operating Margin
1.03%
0pp
FY2026
Diluted EPS
$7.23
+12.1%
FY2026
Operating Cash Flow
$5.17B
+115.9%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | $91.08B | $101.09B | $107.55B | $102.64B | $98.5B | $95.99B | $87.41B | |
| $244.47B | $214.41B | $219.41B | $198.11B | $174.84B | $155.69B | $146.05B | $138.7B | $129.63B | $123.43B | $115B | $96.82B | $85.92B | $96.17B | $103.01B | $98.48B | $94.72B | $92.24B | $83.63B | |
| $9.77B | $8.17B | $7.41B | $6.87B | $6.48B | $6.78B | $6.87B | $6.83B | $7.18B | $6.54B | $6.54B | $5.71B | $5.16B | $4.92B | $4.54B | $4.16B | $3.78B | $3.75B | $3.78B | |
| 3.84% | 3.67% | 3.27% | 3.35% | 3.58% | 4.17% | 4.49% | 4.7% | 5.25% | 5.03% | 5.38% | 5.57% | 5.67% | 4.87% | 4.22% | 4.05% | 3.84% | 3.9% | 4.32% | |
| $6.13B | $5.38B | $5B | $4.8B | $4.51B | $4.53B | $4.57B | $4.48B | $4.6B | $3.78B | $3.65B | $3.24B | $3.03B | $2.88B | $2.68B | $2.53B | $2.4B | $2.33B | $2.34B | |
| $361M | $303M | $264M | $281M | $311M | $428M | $512M | $531M | $574M | $395M | $355M | $191M | $188M | $121M | $79M | $68M | $11M | — | — | |
| $956M | $790M | $710M | $692M | $692M | $783M | $913M | $1B | $1.03B | $717M | $641M | $451M | $459M | $397M | $325M | $313M | $254M | $225.8M | $220M | |
| $106M | $88M | $175M | $95M | $101M | $114M | $122M | $125M | $176M | $56M | $25M | $44M | $31M | $71M | $21M | $15M | $91M | $104.7M | $55.3M | |
| $2.61B | $2.28B | $1.24B | $752M | -$607M | $472M | -$4.1B | $2.06B | $126M | $2.12B | $2.46B | $2.16B | $1.89B | $996M | $1.79B | $1.51B | $1.31B | $1.29B | $1.39B | |
| 1.03% | 1.02% | 0.55% | 0.37% | -0.33% | 0.29% | -2.68% | 1.42% | 0.09% | 1.63% | 2.02% | 2.11% | 2.07% | 0.99% | 1.67% | 1.48% | 1.33% | 1.34% | 1.59% | |
| $3.57B | $3.07B | $1.95B | $1.44B | $85M | $1.26B | -$3.19B | $3.06B | $1.16B | $2.84B | $3.1B | $2.61B | $2.34B | $1.39B | $2.12B | $1.83B | $1.56B | $1.51B | $1.61B | |
| $348M | $215M | $51M | $84M | $147M | $180M | $238M | $294M | $329M | $201M | $178M | $141M | $133M | $123M | $95M | $93M | $113M | $114.4M | $136.1M | |
| $31M | $41M | $9M | -$5M | -$22M | $47M | $1M | -$15M | -$23M | $5M | -$5M | $7M | $46M | $15M | $1M | $22M | $13M | -$13.2M | $38.8M | |
| — | — | — | — | — | — | $2M | $10M | — | — | — | — | — | — | — | — | — | — | — | |
| $2.17B | $2.1B | $1.2B | $663M | -$784M | $323M | -$3.77B | $1.75B | -$228M | $1.92B | $2.28B | $1.97B | $1.8B | $888M | $1.7B | $1.52B | $1.21B | $1.16B | $1.3B | |
| $469M | $532M | $348M | $332M | $153M | -$289M | -$79M | $386M | -$487M | $630M | $845M | $755M | $635M | $553M | $628M | $552M | $625M | $401.6M | $447.9M | |
| $1.71B | $1.56B | $852M | $330M | -$938M | $611M | -$3.7B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | $1.17B | $334M | $1.07B | $959M | $642M | $1.15B | $1.3B | |
| 0.67% | 0.7% | 0.38% | 0.16% | -0.52% | 0.38% | -2.42% | 0.94% | 0.19% | 0.99% | 1.17% | 1.19% | 1.28% | 0.33% | 0.99% | 0.93% | 0.65% | 1.2% | 1.49% | |
| -$9M | $8M | $1M | $1M | $1M | $1M | $3M | $2M | $3M | $6M | $4M | $0 | $0 | — | — | — | — | — | — | |
| $1.7B | $1.57B | $836M | $293M | -$1.02B | $681M | -$3.72B | $1.38B | $289M | $1.28B | $1.33B | $1.12B | $1.17B | $365M | $1.03B | $966M | $630M | $1.02B | $1.39B | |
| USD/shares | $7.27 | $6.48 | $3.48 | $1.27 | -$3.37 | $2.09 | -$12.61 | $4.55 | $0.82 | $4.06 | $4.36 | $3.66 | $3.42 | $0.98 | $3.10 | $2.75 | $1.79 | $3.22 | $3.63 |
| USD/shares | $7.23 | $6.45 | $3.45G | $1.26 | -$3.37 | $2.08 | -$12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 | $3.38 | $0.97 | $3.06 | $2.72 | $1.77 | $3.18 | $3.57 |
| shares | 236M | 241M | 245M | 261M | 279M | 292M | 293M | 300M | 313M | 317M | 327M | 332M | 341M | 341M | 345M | 349M | 359M | 357.6M | 358.2M |
| shares | 237M | 242M | 247M | 262M | 279M | 294M | 293M | 301M | 315M | 320M | 330M | 335M | 345M | 344M | 349M | 353M | 361M | 361.5M | 364M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2026: $13.11B in buybacks, $8.39B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 0.26×
EV/EBIT
—
Peer median 17.93×
P/E (TTM)
—
Peer median 23.31×
Peer medians compare against the 3 similar-size Medical Distribution companies (of 10 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Specialty Solutions | $234,833,000,000 | $204,644,000,000 | $210,019,000,000 | $188,814,000,000 | $164,596,000,000 | — | — | — |
| GMPD | $12,719,000,000 | $12,636,000,000 | $12,381,000,000 | $12,222,000,000 | $13,280,000,000 | — | — | — |
| All Other Segments | $6,792,000,000 | $5,382,000,000 | $4,512,000,000 | $4,021,000,000 | $3,518,000,000 | — | — | — |
| Medical Member | — | — | — | — | — | $16,687,000,000 | $15,444,000,000 | $15,633,000,000 |
| Pharmaceutical | — | — | — | — | — | $145,796,000,000 | $137,495,000,000 | $129,917,000,000 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| United States | $252,639,000,000 | $220,993,000,000 | $225,231,000,000 | $203,440,000,000 | $179,471,000,000 | $157,756,000,000 | $148,707,000,000 | $141,479,000,000 |
| Non Us | $1,705,000,000 | $1,669,000,000 | $1,681,000,000 | $1,617,000,000 | $1,923,000,000 | $4,727,000,000 | $4,232,000,000 | $4,071,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Specialty Solutions | $2,783,000,000 | $2,258,000,000 | $2,015,000,000 | $1,881,000,000 | $1,643,000,000 | — | — | — |
| All Other Segments | $707,000,000 | $516,000,000 | $423,000,000 | $396,000,000 | $390,000,000 | — | — | — |
| GMPD | $258,000,000 | $135,000,000 | $92,000,000 | -$147,000,000 | -$64,000,000 | — | — | — |
| Medical | — | — | — | — | — | — | $663,000,000 | $576,000,000 |
| Medical Member | — | — | — | $111,000,000 | $216,000,000 | $577,000,000 | $663,000,000 | $576,000,000 |
| Pharmaceutical | — | — | — | $1,999,000,000 | $1,770,000,000 | $1,684,000,000 | $1,753,000,000 | $1,834,000,000 |
Operating Margin by Segment (%)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Specialty Solutions | 1.2% | 1.1% | 1% | 1% | 1% | — | — | — |
| GMPD | 2% | 1.1% | 0.7% | -1.2% | -0.5% | — | — | — |
| All Other Segments | 10.4% | 9.6% | 9.4% | 9.8% | 11.1% | — | — | — |
| Medical Member | — | — | — | — | — | 3.5% | 4.3% | 3.7% |
| Pharmaceutical | — | — | — | — | — | 1.2% | 1.3% | 1.4% |
Key facts
CIK
721371
CUSIP
14149Y108
13F (30d)
1345 filings
1303 filers
Visit website
Investor relations